SCHEMBL27068161

SCHEMBL27068161

Cn1cnnc1C1(c2cccc(-n3cc(C4CC4)c4cc(CN5CCOC6(CC6)C5)[nH]c4c3=O)c2)CC(F)(F)C1

nearest known ligand 0.39

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 19/20 0.39
▸ CBL P22681 13/20 0.39
▸ HTR1A P08908 1/20 0.31
▸ HTR1B P28222 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27068120 0.91 CBLB (0.40) CBLBCBL
SCHEMBL27068170 0.91 CBLB (0.40) CBLBCBLHTR1AHTR1B
SCHEMBL27068163 0.90 CBLB (0.39) CBLBCBL
SCHEMBL27068119 0.88 CBLB (0.40) CBLBCBL
SCHEMBL32667018 0.88 CBLB (0.39) CBLBCBLHTR1AHTR1B
SCHEMBL27068111 0.86 CBLB (0.39) CBLBCBLHTR1AHTR1B
SCHEMBL27068109 0.85 CBLB (0.39) CBLBCBL
SCHEMBL27068169 0.85 CBLB (0.38) CBLBCBLHTR1AHTR1B
SCHEMBL27069686 0.85 CBLB (0.42) CBLBCBL
SCHEMBL30728232 0.85 CBLB (0.48) CBLBCBL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2026-01-29 — — US disclosed
WO-2024020034-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028336-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF CBLB, CBL, CBLC CBLB 1/4885CBL 2/4885HTR1A 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback